Original ContributionPotential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma
References (21)
- et al.
Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis
Mod Pathol
(2002) - et al.
Using tumor markers to predict survival of patients with metastatic renal cell carcinoma
J Urol
(2005) - et al.
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Cancer Cell
(2003) - et al.
A high frequency of sequence alterations is due to formalin fixation of archival specimens
Am J Pathol
(1999) - et al.
Low copy number DNA template can render polymerase chain reaction error prone in a sequencedependent manner
J Mol Diagn
(2005) - et al.
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)
J Clin Oncol
(2006) - et al.
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Oncogene
(2000) - et al.
Loss of tumor suppressor protein PTEN during renal carcinogenesis
Int J Cancer
(2002) - et al.
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779
Cancer Res
(2002) - et al.
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin
Mol Cell Biol
(2002)
There are more references available in the full text version of this article.
Cited by (161)
The emerging genetic landscape of renal cell carcinoma
2023, Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing, Second EditionMechanisms of resistance to mTOR inhibitors
2020, Critical Reviews in Oncology/HematologyCharacterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database
2018, Clinical Genitourinary CancerPhase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
2017, European Journal of CancerPhase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
2016, Clinical Genitourinary Cancer
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1558-7673, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Copyright © 2007 Elsevier Inc. All rights reserved.